Key Highlights

  • MNKD shares are up 1.44% to $4.22 in pre-market trading.
  • The company announced a worldwide licensing and collaboration agreement with Rose Pharma to develop ROSE-010 Technosphere, an inhaled rapid-acting GLP-1 receptor agonist for weight management.
  • Rose Pharma gains exclusive global rights to develop and commercialize the asset using MannKind's proprietary Technosphere dry-powder inhalation technology.
  • MannKind will provide pharmaceutical development support through completion of a Phase 1b study, take an Equity stake in Rose Pharma, and secure future Royalty rights.
  • The agreement also provides MannKind with representation on Rose Pharma's board of directors.

Shares Rise on a New GLP-1 Licensing Deal

MannKind (NASDAQ:MNKD) shares are trading higher in pre-market trading after the company announced a worldwide licensing and collaboration agreement with Rose Pharma to develop ROSE-010 Technosphere, an inhaled, rapid-acting glucagon-like peptide-1 receptor agonist for weight management. MannKind is a biopharmaceutical company focused on developing innovative inhaled therapeutic products for patients with endocrine and orphan lung diseases, including diabetes and pulmonary hypertension.

Rose Pharma Gains Exclusive Rights to the Technosphere Platform

Under the agreement, Rose Pharma receives an exclusive, worldwide license to use MannKind's Technosphere dry-powder inhalation technology to develop and commercialize ROSE-010 Technosphere. MannKind will support formulation development and advancement of the program through pharmaceutical development services to completion of a Phase 1b study in weight management.

Capital-Light Structure Includes Equity and Royalty Upside

As part of the transaction, MannKind will receive an equity interest in Rose Pharma and the right to future royalties on potential net sales of ROSE-010 Technosphere, along with representation on Rose Pharma's board of directors. Investors appear encouraged by MannKind's ability to monetize its Technosphere platform in the fast-growing GLP-1 and weight-management space through this capital-light licensing structure.

Trading Volume Points to Genuine Investor Interest

Shares are trading on volume already near the daily average in pre-market hours, even as broader healthcare markets trade only modestly higher amid a cautious macro backdrop of rising oil prices and Inflation concerns. Continued progress toward the Phase 1b study and further details on Rose Pharma's development timeline will likely be the next catalysts for the stock.